Standard Biotools (LAB) Cost of Revenue (2010 - 2026)

Standard Biotools (LAB) has reported Cost of Revenue for 17 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 14.06% year-over-year to $9.6 million in Q2 2026; TTM through Jun 2026 was $41.9 million, a 4.12% decrease from a year earlier, with the FY2025 full-year figure at $42.8 million, down 7.23% from the prior year.
• Cost of Revenue was $9.6 million for Q2 2026 at Standard Biotools, down from $9.8 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $21.4 million in Q1 2024 and troughed at $9.2 million in Q1 2025.
• A 5-year average of $13.0 million and a median of $12.6 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 66.32% in 2024 and plunged 57.04% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $15.9 million in 2022, then fell by 6.45% to $14.8 million in 2023, then dropped by 9.51% to $13.4 million in 2024, then fell by 7.5% to $12.4 million in 2025, then fell by 22.91% to $9.6 million in 2026.
• The last three Cost of Revenue figures came in at $9.6 million (Q2 2026), $9.8 million (Q1 2026), and $12.4 million (Q4 2025), per Business Quant data.